## Carlo Ajm Gaillard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6684895/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 798-807.	2.9	5
2	Associations between depressive symptoms and disease progression in older patients with chronic kidney disease: results of the EQUAL study. CKJ: Clinical Kidney Journal, 2022, 15, 786-797.	2.9	4
3	lron deficiency, with and without anaemia, across strata of kidney function in kidney transplant recipients. Nephrology Dialysis Transplantation, 2021, 36, 2342-2344.	0.7	1
4	Changes in cerebral oxygenation and cerebral blood flow during hemodialysis – A simultaneous near-infrared spectroscopy and positron emission tomography study. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 328-340.	4.3	39
5	Evaluation of diagnostic and therapeutic management of hypertensive crises in a Dutch emergency department. European Journal of Emergency Medicine, 2020, 27, 66-68.	1.1	Ο
6	Creatinine synthesis rate and muscle strength and self-reported physical health in dialysis patients. Clinical Nutrition, 2020, 39, 1600-1607.	5.0	8
7	Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia. Blood Advances, 2020, 4, 1678-1682.	5.2	13
8	Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients. ESC Heart Failure, 2020, 7, 1224-1233.	3.1	20
9	Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk. Kidney Medicine, 2020, 2, 341-353.	2.0	24
10	Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrology Dialysis Transplantation, 2019, 34, 2057-2065.	0.7	73
11	Epoetin Beta and Câ€Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease. Journal of the American Heart Association, 2019, 8, e011130.	3.7	15
12	Association Between Renal Function and Troponin T Over Time in Stable Chronic Kidney Disease Patients. Journal of the American Heart Association, 2019, 8, e013091.	3.7	37
13	Administration of Intravenous Iron Formulations Induces Complement Activation in-vivo. Frontiers in Immunology, 2019, 10, 1885.	4.8	8
14	The Prevalence of Intradialytic Hypotension in Patients on Conventional Hemodialysis: A Systematic Review with Meta-Analysis. American Journal of Nephrology, 2019, 49, 497-506.	3.1	77
15	Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study. PLoS Medicine, 2019, 16, e1002818.	8.4	16
16	The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research. Frontiers in Physiology, 2019, 10, 304.	2.8	33
17	Active smoking and macrocytosis in the general population: Two populationâ€based cohort studies. American Journal of Hematology, 2019, 94, E45-E48.	4.1	5
18	Erythropoietin Is Associated with a Decline in the iFGF23/cFGF23 Ratio in Patients with Various Hereditary Hemolytic Anemias, Blood, 2019, 134, 4793-4793	1.4	0

#	Article	IF	CITATIONS
19	Hemodialysis Induces an Acute Decline in Cerebral Blood Flow in Elderly Patients. Journal of the American Society of Nephrology: JASN, 2018, 29, 1317-1325.	6.1	132
20	Active Smoking and Hematocrit and Fasting Circulating Erythropoietin Concentrations in the General Population. Mayo Clinic Proceedings, 2018, 93, 337-343.	3.0	16
21	FP387IRON DEFICIENCY, ERYTHROPOIETIN, AND FIBROBLAST GROWTH FACTOR 23 IN THE GENERAL POPULATION. Nephrology Dialysis Transplantation, 2018, 33, i164-i164.	0.7	Ο
22	Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1680-1692.	4.5	11
23	SaO005ADMINISTRATION OF INTRAVENOUS IRON PREPARATIONS INDUCES COMPLEMENT ACTIVATION IN PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i316-i316.	0.7	Ο
24	Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. BMC Nephrology, 2017, 18, 24.	1.8	13
25	Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. Acta Physiologica, 2017, 220, 382-393.	3.8	10
26	Urinary prednisolone excretion is a determinant of serum hepcidin levels in renal transplant recipients. American Journal of Hematology, 2017, 92, E173-E175.	4.1	2
27	High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients. Diabetes Care, 2017, 40, 894-901.	8.6	27
28	Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. Nephrology Dialysis Transplantation, 2017, 32, 1530-1539.	0.7	38
29	The Effect of Renal Function and Hemodialysis Treatment on Plasma Vasopressin and Copeptin Levels. Kidney International Reports, 2017, 2, 410-419.	0.8	24
30	Low Urinary Creatinine Excretion Is Associated With Self-Reported Frailty in Patients With Advanced Chronic Kidney Disease. Kidney International Reports, 2017, 2, 676-685.	0.8	23
31	High serum PCSK9 is associated with increased risk of new-onset diabetes after transplantation in renal transplant recipients. Atherosclerosis, 2017, 263, e254-e255.	0.8	0
32	C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2017, 28, 3639-3646.	6.1	46
33	Distinct in vitro Complement Activation by Various Intravenous Iron Preparations. American Journal of Nephrology, 2017, 45, 49-59.	3.1	56
34	Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial. Clinical Nephrology, 2017, 88, 301-310.	0.7	17
35	Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment. PLoS ONE, 2017, 12, e0169263.	2.5	19
36	Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial. PLoS ONE, 2016, 11, e0157063.	2.5	26

#	Article	IF	CITATIONS
37	Iron deficiency, anemia, and mortality in renal transplant recipients. Transplant International, 2016, 29, 1176-1183.	1.6	38
38	Cardiac Hepcidin Expression Associates with Injury Independent of Iron. American Journal of Nephrology, 2016, 44, 368-378.	3.1	18
39	Urinary potassium excretion, renal ammoniagenesis, and risk of graft failure and mortality in renal transplant recipients. American Journal of Clinical Nutrition, 2016, 104, 1703-1711.	4.7	35
40	Causes and Consequences of Interdialytic weight gain. Kidney and Blood Pressure Research, 2016, 41, 710-720.	2.0	33
41	Association of hepcidinâ€25 with survival after kidney transplantation. European Journal of Clinical Investigation, 2016, 46, 994-1001.	3.4	6
42	Feasibility of measuring renal blood flow by phase-contrast magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease. European Radiology, 2016, 26, 683-692.	4.5	6
43	Nutritional Status in Nocturnal Hemodialysis Patients – A Systematic Review with Meta-Analysis. PLoS ONE, 2016, 11, e0157621.	2.5	9
44	Neuronal Nitric Oxide Synthase-Dependent Amelioration of Diastolic Dysfunction in Rats with Chronic Renocardiac Syndrome. CardioRenal Medicine, 2015, 5, 69-78.	1.9	4
45	Changes in Plasma Copeptin Levels during Hemodialysis: Are the Physiological Stimuli Active in Hemodialysis Patients?. PLoS ONE, 2015, 10, e0127116.	2.5	16
46	Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure. PLoS ONE, 2015, 10, e0128994.	2.5	15
47	The Effects of Kidney Transplantation on Sleep, Melatonin, Circadian Rhythm and Quality of Life in Kidney Transplant Recipients and Living Donors. Nephron, 2015, 129, 6-15.	1.8	30
48	Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and) Tj ETQq0 0 0 rgB1 Heart Journal 2015, 169, 693-701, 63	[  Qverloc  2.7	10 Tf 50 30
49	An observational study on disturbed peripheral circadian rhythms in hemodialysis patients. Chronobiology International, 2015, 32, 848-857.	2.0	21
50	Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease: Reliable Indicators of Vasopressin Activity and Disease Prognosis?. American Journal of Nephrology, 2015, 41, 248-256.	3.1	15
51	Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2015, 66, 792-801.	1.9	36
52	FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation, 2014, 29, 2075-2084.	0.7	226
53	The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation, 2014, 29, 843-850.	0.7	31
54	Effect of Nocturnal Haemodialysis on Body Composition. Nephron Clinical Practice, 2014, 128, 171-177.	2.3	7

#	Article	IF	CITATIONS
55	Cardiorenal syndrome—current understanding and future perspectives. Nature Reviews Nephrology, 2014, 10, 48-55.	9.6	114
56	Response to letter by Balta et al International Journal of Cardiology, 2013, 169, 89.	1.7	2
57	Red cell distribution width is associated with physical inactivity and heart failure, independent of established risk factors, inflammation or iron metabolism; the EPIC—Norfolk study. International Journal of Cardiology, 2013, 168, 3550-3555.	1.7	62
58	Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP. European Respiratory Journal, 2013, 41, 123-130.	6.7	52
59	Longâ€ŧerm effects of melatonin on quality of life and sleep in haemodialysis patients ( <scp>M</scp> elody study): a randomized controlled trial. British Journal of Clinical Pharmacology, 2013, 76, 668-679.	2.4	44
60	Red blood cell: barometer of cardiovascular health?. Cardiovascular Research, 2013, 98, 3-4.	3.8	7
61	Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series. CKJ: Clinical Kidney Journal, 2013, 6, 473-477.	2.9	6
62	Taxol <sup>®</sup> -induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor <sup>®</sup> EL. Nanomedicine, 2013, 8, 1127-1135.	3.3	22
63	Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Chronic Cardiorenal Failure is Correlated with Endogenous Erythropoietin Levels and Decreases in Response to Low-Dose Erythropoietin Treatment. Kidney and Blood Pressure Research, 2012, 36, 344-354.	2.0	18
64	A role for activated endothelial cells in red blood cell clearance: implications for vasopathology. Haematologica, 2012, 97, 500-508.	3.5	64
65	Atherosclerotic renal artery stenosis is prevalent in cardiorenal patients but not associated with left ventricular function and myocardial fibrosis as assessed by cardiac magnetic resonance imaging. BMC Cardiovascular Disorders, 2012, 12, 76.	1.7	7
66	Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents. PLoS ONE, 2012, 7, e39783.	2.5	47
67	The role of melatonin treatment in chronic kidney disease. Frontiers in Bioscience - Landmark, 2012, 17, 2644.	3.0	53
68	Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Failure Reviews, 2012, 17, 161-175.	3.9	83
69	New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Failure Reviews, 2012, 17, 191-201.	3.9	64
70	Determinants of Red Cell Distribution Width (RDW) in Cardiorenal Patients: RDW is Not Related to Erythropoietin Resistance. Journal of Cardiac Failure, 2011, 17, 626-633.	1.7	60
71	The role of renal function loss on circadian misalignment of cytokines EPO, IGF-1, IL-6 and TNF-alfa in chronic renal disease. Neuroendocrinology Letters, 2011, 32, 148-53.	0.2	3
72	Dutch guideline for the management of hypertensive crisis 2010 revision. Netherlands Journal of Medicine, 2011, 69, 248-55.	0.5	30

#	Article	IF	CITATIONS
73	Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability. Experimental Hematology, 2010, 38, 282-291.	0.4	27
74	Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (CREAM study). Nephrology Dialysis Transplantation, 2010, 25, 513-519.	0.7	74
75	Hepcidinâ€25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patientsâ€. European Journal of Heart Failure, 2010, 12, 943-950.	7.1	67
76	High cumulative incidence of cancer in patients with cardioâ€renalâ€anaemia syndrome. European Journal of Heart Failure, 2010, 12, 855-860.	7.1	8
77	Hemoglobin Variability in Patients with Chronic Kidney Disease in the Netherlands. International Journal of Artificial Organs, 2009, 32, 787-793.	1.4	15
78	Time for first antibiotic dose is not predictive for the early clinical failure of moderate–severe community-acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 913-919.	2.9	32
79	The Cardiorenal Syndrome. Journal of the American College of Cardiology, 2009, 53, 1340.	2.8	5
80	Renal Venous Congestion and Renal Function in Congestive Heart Failure. Journal of the American College of Cardiology, 2009, 54, 1632.	2.8	13
81	Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nature Clinical Practice Nephrology, 2008, 4, 47-57.	2.0	152
82	Angiotensin II Type 1 Receptor Blockade Improves Hyperglycemia-Induced Endothelial Dysfunction and Reduces Proinflammatory Cytokine Release From Leukocytes. Journal of Cardiovascular Pharmacology, 2007, 49, 6-12.	1.9	30
83	Application of leukocyte transcriptomes to assess systemic consequences of risk factors for cardiovascular disease. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1109-20.	2.3	14
84	Broadly Altered Gene Expression in Blood Leukocytes in Essential Hypertension Is Absent During Treatment. Hypertension, 2004, 43, 947-951.	2.7	73
85	Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment. Journal of Human Hypertension, 2004, 18, 857-863.	2.2	5
86	Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Annals of Neurology, 2003, 53, 325-336.	5.3	169
87	Intensive Lipid Lowering by Statin Therapy Does Not Improve Vasoreactivity in Patients With Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 799-804.	2.4	75
88	Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia, 2002, 45, 1004-1010.	6.3	124
89	Variant esp gene as a marker of a distinct genetic lineage of vancomycinresistant Enterococcus faecium spreading in hospitals. Lancet, The, 2001, 357, 853-855.	13.7	291
90	Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients*. Critical Care Medicine, 2001, 29, S193-S198.	0.9	1

#	Article	IF	CITATIONS
91	Prevention of Ventilator-associated Pneumonia by Oral Decontamination. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 382-388.	5.6	370
92	Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. American Journal of Medicine, 2000, 108, 421-423.	1.5	90
93	Cross-colonisation with Pseudomonas aeruginosa of patients in an intensive care unit. Thorax, 1998, 53, 1053-1058.	5.6	105
94	Prediction of Clinical Severity and Outcome of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1026-1031.	5.6	60
95	Is nondipping in 24 h ambulatory blood pressure related to cognitive dysfunction?. Journal of Hypertension, 1998, 16, 1425-1432.	0.5	27
96	Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin. Journal of Hypertension, 1998, 16, 45-50.	0.5	123
97	The Systemic Inflammatory Response in the Development of Ventilator-Associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1105-1113.	5.6	95
98	Role of Colonization of the Upper Intestinal Tract in the Pathogenesis of Ventilator-Associated Pneumonia. Clinical Infectious Diseases, 1997, 24, 309-319.	5.8	161
99	Indications for antibiotic use in ICU patients: a one-year prospective surveillance. Journal of Antimicrobial Chemotherapy, 1997, 39, 527-535.	3.0	160
100	Implementation of Bronchoscopic Techniques in the Diagnosis of Ventilator-associated Pneumonia to Reduce Antibiotic Use. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1820-1824.	5.6	153
101	Can the blood pressure predict cognitive task performance in a healthy population sample?. Journal of Hypertension, 1997, 15, 1069-1076.	0.5	65
102	Natriuretic effect of nitrendipine is preceded by transient systemic and renal hemodynamic effects. Cardiovascular Drugs and Therapy, 1997, 11, 33-38.	2.6	5
103	Value of phenotyping methods as an initial screening ofPseudomonas aeruginosa in epidemiologic studies. Infection, 1997, 25, 350-354.	4.7	18
104	Stress bleeding prophylaxis in the ICU: Obligate or obsolete?. Netherlands Journal of Medicine, 1996, 48, 4-7.	0.5	1
105	Repeated automatic versus ambulatory blood pressure measurement:the effects of age and sex in a normal ageing population. Journal of Hypertension, 1996, 14, 31???40.	0.5	5
106	Assessment of gastric acidity in intensive care patients: Intermittent pH registration cannot replace continuous pH monitoring. Intensive Care Medicine, 1996, 22, 220-225.	8.2	8
107	Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients American Journal of Respiratory and Critical Care Medicine, 1996, 154, 1339-1346.	5.6	177
108	Intermittent enteral feeding: the influence on respiratory and digestive tract colonization in mechanically ventilated intensive-care-unit patients American Journal of Respiratory and Critical Care Medicine, 1996, 154, 394-399.	5.6	127

#	Article	IF	CITATIONS
109	Colonization and infection with Enterococcus faecalis in intensive care units: the role of antimicrobial agents. Antimicrobial Agents and Chemotherapy, 1995, 39, 2783-2786.	3.2	33
110	The role of intragastric acidity and stress ulcus prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized, double-blind study of sucralfate versus antacids American Journal of Respiratory and Critical Care Medicine, 1995, 152, 1825-1834.	5.6	152
111	Editorial. Netherlands Journal of Medicine, 1995, 46, 1-3.	0.5	7
112	A Typical Case of Cross-Acquisition? The Importance of Genotypic Characterization of Bacterial Strains. Infection Control and Hospital Epidemiology, 1995, 16, 415-416.	1.8	3
113	The Stomach Is Not a Source for Colonization of the Upper Respiratory Tract and Pneumonia in ICU Patients. Chest, 1994, 105, 878-884.	0.8	178
114	Colonization in patients receiving and not receiving topical antimicrobial prophylaxis American Journal of Respiratory and Critical Care Medicine, 1994, 150, 1332-1340.	5.6	61
115	Continuous enteral feeding counteracts preventive measures for gastric colonization in intensive care unit patients. Critical Care Medicine, 1994, 22, 939-944.	0.9	68
116	SHORT-TERM RENAL HEMODYNAMIC CHANGES IN PATIENTS RECEIVING A RENAL ALLOGRAFT. Transplantation, 1994, 57, 1661-1663.	1.0	1
117	Topical antimicrobial prophylaxis of nosocomial pneumonia in mechanically ventilated patients. Microbiological observations. Infection, 1993, 21, 137-139.	4.7	25
118	Clinical experiences with trandolapril. American Heart Journal, 1993, 125, 1542-1546.	2.7	12
119	Enterococcus faecalis Pneumonia Complicating Topical Antimicrobial Prophylaxis. New England Journal of Medicine, 1993, 328, 209-210.	27.0	69
120	Recurrent postpartum renal failure in a renal allograft. Transplantation, 1993, 56, 1017-20.	1.0	0
121	Diagnosis of pneumonia in mechanically ventilated patients: clinical judgement or bronchoscopy?. Netherlands Journal of Medicine, 1993, 43, 97-9.	0.5	0
122	Membranous glomerulonephritis. Towards tailor-made treatment?. Netherlands Journal of Medicine, 1993, 42, 109-11.	0.5	2
123	The Diuretic Effect of Calcium Entry Blockade in Normals and Hypertensive Patients Tohoku Journal of Experimental Medicine, 1992, 166, 135-146.	1.2	2
124	ACUTE TUMOUR LYSIS SYNDROME IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AFTER A SINGLE DOSE OF PREDNISONE. British Journal of Haematology, 1991, 77, 122-123.	2.5	28
125	Chronic hyperinsulinemia and blood pressure. Interaction with catecholamines?. Hypertension, 1990, 15, 519-527.	2.7	128
126	Opposite effects of enalapril and nitrendipine on natriuretic response to atrial natriuretic factor. Renal function evaluated with clearance studies in humans Hypertension, 1989, 13, 173-180.	2.7	11

#	Article	IF	CITATIONS
127	Blunted natriuretic response and low blood pressure after atrial natriuretic factor in early cirrhosis. Hepatology, 1989, 10, 148-153.	7.3	32
128	Renal response to infusion versus repeated bolus injections of atrial natriuretic factor in man. European Journal of Clinical Pharmacology, 1989, 36, 195-197.	1.9	6
129	Small intra- and large inter-individual variability in lithium clearance in humans. Kidney International, 1989, 35, 1183-1188.	5.2	21
130	Lithium clearance during variations in sodium intake in man: effects of sodium restriction and amiloride. European Journal of Clinical Investigation, 1988, 18, 279-283.	3.4	44
131	Enhanced natriuretic effect of atrial natriuretic factor during mineralocorticoid escape in humans Hypertension, 1988, 12, 450-456.	2.7	18
132	Enalapril attenuates natriuresis of atrial natriuretic factor in humans Hypertension, 1988, 11, 160-165.	2.7	39
133	Atrial natriuretic peptide and sodium intake: blunted effects in the normal sodium-retaining kidney. Netherlands Journal of Medicine, 1987, 30, 10-6.	0.5	2
134	Renal response to atrial natriuretic peptide in nephrotic syndrome. Nephrology Dialysis Transplantation, 1987, 2, 510-4.	0.7	11